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Summary 
Structural similarity between viral T cell epitopes and 
self-peptides could lead to the induction of an autoag- 
gressive T cell response. Based on the structural re- 
quirements for both MHC class II binding and TCR rec- 
ognition of an immunodominant myelin basic protein 
(MBP) peptide, criteria for a data base search were 
developed in which the degeneracy of amino acid side 
chains required for MHC class II binding and the con- 
servation of those required for T cell activation were 
considered. A panel of 129 peptides that matched the 
molecular mimicry motif was tested on seven MBP- 
specific T cell clones from multiple sclerosis patients. 
Seven viral and one bacterial peptide efficiently acti- 
vated three of these clones. Only one peptide could 
have been identified as a molecular mimic by sequence 
alignment. The observation that a single T cell recep- 
tor can recognize quite distinct but structurally related 
peptides from multiple pathogens has important impli- 
cations for understanding the pathogenesis of autoim- 
munity. 
Introduction 
Activation of autoreactive T cells is a critical event in the 
induction of autoimmunity. In animal models of T cell- 
mediated autoimmunity, disease can be transferred only 
with activated but not with resting T cells specific for a 
central nervous system (CNS)-specific autoantigen (re- 
viewed by Zamvil and Steinman, 1990). Resting autoreac- 
tive T cells are part of the normal immune repertoire and 
do not induce disease as the blood-brain barrier limits 
access to the CNS to activated T cells (Schluesener and 
Wekerle, 1985; Burns et al., 1983; Ota et al., 1990; Martin 
et al., 1990; Pette et al., 1990). This protective mechanism 
makes circulating self-reactive T cells "ignorant" of the 
complex set of tissue-specific self-antigens hidden behind 
the blood-brain barrier. Invasion of the CNS requires auto- 
reactive T cells to be activated in the peripheral immune 
system. This activation occurs in the absence of their nom- 
inal self-antigen, which is sequestered in the CNS (Wek- 
erie et al., 1986; Hickey et al., 1991). Two mechanisms 
could account for the activation and clonal expansion of 
autoreactive T cells in the periphery: activation by bacterial 
or viral superantigens that trigger T cells bearing particular 
T cell receptor VI~ segments (Brocke et al., 1993; Cole 
and Griffiths, 1993; Conrad et al., 1994), or activation by 
viral or bacterial peptides that have sufficient sequence 
similarity with an immunodominant self-peptide (molecu- 
lar mimicry) (Oldstone, 1990). 
A large body of clinical and epidemiological evidence 
indicates that infections are important in the induction of 
autoimmunity. Particular viral infections frequently pre- 
cede autoimmune myocarditis and type I diabetes (IDDM) 
(Rose et al., 1986; Ray et al., 1980). Also, an inflammatory 
CNS disease can follow infection with a number of com- 
mon viral pathogens, such as measles and rubella. The 
absence of virus in the CNS and reactivity to myelin basic 
protein (MBP) in these patients suggest an autoimmune 
mechanism (Johnson et al., 1984). Environmental agents 
also influence the risk of developing multiple sclerosis 
(MS) as demonstrated by migration studies. Individuals 
that migrate after age 15 carry the risk for developing MS 
associated with their geographic origin, while individuals 
who migrate earlier in life acquire the risk of the geographi- 
cal region to which they migrated (Kurtzke, 1985). These 
studies are consistent with the hypothesis that a group of 
pathogens that are relatively ubiquitous in a certain geo- 
graphic region influence the risk of developing MS. 
Recent immunological studies suggest that MBP may 
be one of the important target antigens in the immuno- 
pathogenesis of MS. Several studies have demonstrated 
that MBP-specific T cells are clonally expanded in MS 
patients and in an in vivo activated state (Allegretta et al., 
1990; Wucherpfennig et al., 1994b; Zhang et al., 1994). 
Reactivity with the immunodominant MBP(84-102) pep- 
tide is found predominantly in subjects carrying HLA-DR2, 
a genetic marker for susceptibility to MS. The MBP(84- 
102) epitope can also be presented by other major histo- 
compatibility complex (MHC) class II antigens, including 
HLA-DQ1 (Ota et al., 1990; Martin et al., 1990; Pette et 
al., 1990; Wucherpfennig et al., 1994a). In vivo, the T cell 
response to this peptide appears to be dominated by a 
few expanded clones. The mechanism(s) leading to clonal 
expansion of M BP-reactive T cells remains to be identified, 
but could involve recognition of viral peptides with suffi- 
cient structural similarity to the immunodominant MBP 
peptide. Viruses that cause latent and/or persistent infec- 
tions (such as the herpes simplex and Epstein-Barr vi- 
ruses) would be particularly interesting candidates, as 
they may permit chronic antigenic stimulation of these au- 
toreactive T cell clones. The initiation of autoimmunity by 
such a mechanism could then lead to sensitization to other 
CNS self-antigens by determinant spreading (Lehmann et 
al., 1992; Kaufman et al., 1993; Tisch et al., 1993). 
Structural characterization of the immunodominant 
MBP(85-99) peptide identified residues critical for MHC 
class II binding and for T cell receptor (TCR) recognition 
(Wucherpfennig et al., 1994a). The MHC class II and TCR 
contact residues of the immunodominant MBP(85-99) 
peptide were then subjected to mutational analysis in or- 
der to define the set of amino acids permitted at each 
critical position. These structural criteria, together with the 
knowledge that amino acid side chains required for bind- 
ing to MHC molecules are degenerate, were used to 
search a protein sequence data base. Selected viral and 
bacterial peptides were tested for their ability to activate 
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human MBP(85-99)-specific T cell clones that had been 
established from blood T cells of MS patients. Of 129 pep- 
tides synthesized, seven viral peptides and one bacterial 
peptide that met the criteria were found to efficiently stimu- 
late MBP-specific T cell clones. These viral and bacterial 
peptides therefore act as molecular mimics of the immuno- 
dominant MBP(85-99) peptide. Molecular mimicry of this 
immunodominant self-peptide by viruses therefore pre- 
sents a possible mechanism for the induction of autoimmu- 
nity in MS. 
Results 
Structural Characterization of the Immunodominant 
T Cell Epitope of Human MBP 
Susceptibility to MS is associated with HLA-DR2 (DRA, 
DRB1*1501, the most common subtype of DR2) (Spiel- 
man and Nathenson, 1982; Olerup et al., 1989). This MHC 
class II molecule may play a critical role in the immuno- 
pathogenesis of MS by presenting immunodominant self- 
peptides to autoreactive T cells. Following injection of 
MBP in experimental nimals, T cells specific for immuno- 
dominant peptides of MBP mediate an inflammatory re- 
sponse in the CNS that can be accompanied by marked 
demyelination (reviewed by Zamvil and Steinman, 1990). 
In previous tudies, two regions of human M BP were found 
to be immunodominant (residues 84-102 and 143-168) 
(Ota et al., 1990; Pette et al., 1990; Martin et al., 1990; 
Wucherpfennig et al., 1994a). Reactivity to the MBP(84- 
102) peptide was predominantly seen in subjects carrying 
HLA-DR2. Using L cell transfectants as antigen-present- 
ing cells, HLA-DR2b (DRA, DRBl*1501) was found to 
serve as the restriction element for these MBP(84-102)- 
specific T cell clones. The MBP(84-102) peptide bound 
with high affinity to the HLA-DR2b molecule with two hy- 
drophobic residues serving as the primary anchors (Val-89 
and Phe-92 in the MBP(85-99) peptide) (Figure 1) (Wuch- 
erpfennig et al., 1994a; Vogt et al., 1994). At the first an- 
chor position, Val-89 could be substituted by other ali- 
phatic amino acids (leucine and isoleucine), as well as by 
methionine and phenylalanine; alanine was tolerated at 
this position but reduced the affinity of the peptide for H LA- 
DR2b. At the second anchor position, all aliphatic and 
aromatic residues were permitted; again alanine was toler- 
ated but resulted in a loss of binding affinity. 
A mutational analysis of putative TCR contact points 
demonstrated that Phe-91 and Lys-93 were the primary 
TCR contacts for the MBP(85-99)-specific lones; other 
residues such as Val-88 and His-90 were important for 
some clones but not for others. Substitution of Phe-91 by 
alanine abolished TCR recognition for all clones; some 
clones tolerated conservative substitutions (e.g., tyrosine 
or aliphatic amino acids) while other clones did not. Substi- 
tution of Lys-93 by arginine was tolerated by most T cell 
clones, but more drastic changes frequently resulted in a 
partial or complete loss of T cell reactivity. This analysis 
demonstrated that His-90, Phe-91, and Lys-93 were the 
primary TCR contact residues, while Val-89 and Phe-92 
were the primary MHC contact residues (Figure 1). 
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Figure 1. Peptide Motifs Required for MHC Class II Binding and TCR 
Recognition of the Immunodominant MBP(85-99) Peptide 
The MBP(88-97) segment is critical for MHC class II binding and TCR 
recognition by HLA-DR2-and HLA-DQl-restricted clones. Peptide resi- 
dues His-90, Phe-91, and Lys 93 appear to be critical TCR contacts 
for both sets of clones; hydrophobic amino acids are important for 
anchoring the peptide to the MHC class II molecules. Based on the 
recognition motifs and a detailed mutational nalysis, molecular mim- 
icry motifs were defined for searching aprotein data base for viral and 
bacterial sequences that fit these criteria. The different sets represent 
search criteria for different sets of clones with different preferences at 
TCR contact points (Val-88, His-90, Phe-91, and Lys-93). Hydrophobic 
amino acids (aliphatic and/or aromatic) were specified for the two major 
MHC anchor esidues (Val-89 and Phe-92). The following number of 
peptides were synthesized for each set: set 1, 24 peptides; set 2, 46 
peptides; set 3, 59 peptides. Random peptide sequences would be 
expected to match the motifs at the following frequencies: et 1, 1: 
40,000; set 2, 1:27,750; set 3, 1:3692 sequences. 
Can Structural Motifs Be Used to Identify Viral 
Peptides That Activate MBP-Specific T Cells? 
Based on this structural characterization of the immuno- 
dominant MBP(85-99) peptide, a set of structural criteria 
(i.e., a molecular mimicry motif) was developed to search 
a protein data base for viral and bacterial peptides that 
matched these requirements. These search criteria fo- 
cused on the core region of the peptide, residues 88-93, 
which contained the MHC and TCR contacts common to 
all clones. In the first set, aliphatic amino acids were al- 
lowed at the first MHC anchor residue (Val-89); aliphatic 
and aromatic residues were permitted at the second MHC 
anchor (Phe-92). For the TCR contacts, Phe-91 was abso- 
lutely conserved, Lys-93 could only be substituted by argi- 
nine, while His-90 and Val-88 could be substituted by sev- 
eral structurally related amino acids (Figure 1). 
The second set of criteria omitted Val-88 as a TCR con- 
tact residue (used only by some clones) and also permitted 
aromatic amino acids at the first MHC anchor (Val-89). 
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This was done since the MBP(85-99) peptide is pre- 
sented by different HLA-DR2 subtypes: presentation by 
DRB1 * 1501 requires an aliphatic amino acid or phenylala- 
nine at this position, while aliphatic and all aromatic resi- 
dues at this position can serve as anchor for DRB1 "1602 
(K. W. W. and J. L. S., unpublished ata). This difference 
relates to the size of the primary pocket binding this hy- 
drophobic residue and is determined by the Val/Gly dimor- 
phism at DRI386 (Val in "1501 and Gly in "1602) (Busch 
et al., 1991; Brown et al., 1993). 
The third set represented a modification of the TCR con- 
tact residues preferred by a subgroup of MBP(85-99)- 
specific clones. For these clones, Lys-93 was absolutely 
conserved while Phe-91 could be substituted by some aro- 
matic or aliphatic amino acids (Figure 1). 
These search criteria also matched well with the struc- 
tural requirements for a HLA-DQl-restricted clone specific 
for the MBP(85-99) peptide. This clone required the same 
minimal peptide segment as DR2-restricted clones (resi- 
dues 87-97). As in the DR2-restricted clones, His-90, Phe- 
91, and Lys-93 appeared to be the primary TCR contact 
residues (unpublished ata). Based on pool sequencing 
of naturally processed peptides bound to HLA-DQ1, three 
hydrophobic positions (at position 1, 4, and 7 relative to 
the first anchor; Val-89, Phe-92, and lie 95 in the MBP(85- 
99) peptide) are thought o contribute to binding (K. Falk 
and O. RStschke, submitted). Substitution of these hy- 
drophobic positions by aspartic acid greatly diminished 
the stimulatory capacity of the peptide, while substitutions 
by other hydrophobic amino acids were tolerated. These 
data suggest that the MBP(85-99) peptide is bound in a 
similar fashion to HLA-DR2b and HLA-DQ1 and that the 
same peptide residues are critical for interaction with the 
TCR. 
These complex criteria were used to search protein data 
bases (PIR and SwissProt) using the Genetics Computer 
Group software (program: findpatterns). More than 600 
sequences of viral and bacterial origin were identified that 
matched these criteria. From this pool, sequences were 
selected based on the following criteria: one, viruses 
known to cause human pathology; two, viruses prevalent 
in the Northern Hemisphere where MS occurs most fre- 
quently; three, selected bacterial sequences associated 
with inflammatory CNS disease (such as Borrelia burgdorf- 
eri) and with invasive infections (such as Staphylococcus 
aureus, Klebsiella pneumoniae, and Pseudomonas aeru- 
ginosa). Not included were most viruses that cause infec- 
tions in tropical countries, sequences derived from vac- 
cinia virus as well as a large number of sequences from 
Escherichia coil, which is part of the normal intestinal f ora. 
When multiple antigenic variants were present, one or sev- 
eral sequences that best fit the search criteria were cho- 
sen. The selected peptides were synthesized by Pin- 
Technology on a 1 mg scale (Chiron Mimotopes, San 
Diego); 70 peptides were made for criteria sets 1 and 2 
(Figure 1) and 59 peptides for set 3. 
Activation of Human MBP(85-99)-Specific T Cell 
Clones by Viral Mimicry Peptides 
Peptides were tested for their ability to activate human 
MBP(85-99)-specific T cell clones that had been pre- 
viously established from blood T cells of two patients with 
relapsing-remitting MS (Wucherpfennig et al., 1994a, 
1994b). As previously, homozygous B cell lines that ex- 
pressed DR2 (DRB1*1501 or DRB1 "1602) or DQ1 were 
used as antigen-presenting cells in these T cell prolifera- 
tion experiments (Wucherpfennig et al., 1994a). Seven 
clones were tested with the 70 viral/bacterial peptides from 
sets 1 and 2. As expected, all clones were activated bythe 
MBP(85-99) peptide that served as the positive control. 
Interestingly, three of the seven clones tested were also 
efficiently activated by several viral/bacterial peptides (Ta- 
bles 1 and 2, data for five clones are shown). The first clone 
(Hy.1B11) recognized the MBP(85-99) peptide on HLA- 
DQ1; clones Hy.2E11 and Hy.1G11 were HLA-DR2 re- 
stricted (Wucherpfennig et al., 1994a). Among the first 
70 peptides tested, three mimicry peptides stimulated the 
DQ1 -restricted clone; two mimicry peptides from Epstein- 
Barr virus (EBV) and influenza type A virus stimulated two 
of the DR2-restricted T cell clones (Table 1). Among the 
second group of peptides (set 3, 59 peptides), one mimicry 
peptide from human papillomavirus was identified for the 
DQl-restricted clone, while a reovirus peptide and a her- 
pes simplex virus peptide were identified for the DR2- 
restricted clones (Hy.2E11 and Hy.1G11, respectively) 
(Table 2; data not shown). This second group of peptides 
has not yet been tested with the other DR2-restricted 
clones. 
Taken together, the DQl-restricted T cell clone recog- 
nized five structurally related peptides: the immunodomi- 
nant MBP(85-99) peptide, three viral peptides (from 
herpes simplex, adenovirus type 12, and human papillo- 
mavirus) and a ~ bacterial peptide (Pseudomonas aerugi- 
nosa). Two of the DR2-restricted clones were activated 
by four peptides. Both clones recognized the MBP(85- 
99) peptide as well as mimicry peptides from EBV and 
influenza virus. In addition, each clone recognized a viral 
peptide from reovirus (T cell clone Hy.2E11) and herpes 
simplex virus (clone Hy.IG11) (Table 2). 
Efficient T Cell Stimulation by Mimicry Peptides 
If viral/bacterial mimicry peptides are indeed important for 
the initiation of autoimmunity, they have to be capable 
of potent T cell stimulation that results in marked clonal 
expansion of autoaggressive T cell clones. The stimulatory 
capacity of the mimicry peptides was therefore compared 
with the MBP(85-99) peptide in a titration experiment (Fig- 
ure 2). The peptides were found to be efficient stimulators 
of these MBP-specific T cell clones; in particular, the EBV 
peptide (DR2-restricted clones) and the adenovirus pep- 
tide (DQl-restricted clone) were similar to the MBP(85- 
99) peptide in their stimulatory capacity. These results 
demonstrate that T cell mimicry is not the result of a minor 
degree of "cross-reactivity" but rather the result of struc- 
tural similarity sufficient for potent T cell activation. 
The efficient stimulation of MBP(85-99)-specific T cell 
clones by these peptides also argues against he presence 
of a small contaminating T cell population that responds 
to these peptides. To ensure that the peptides were indeed 
seen by a single T cell clone, both T cell clones were 
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Table 1. Screening of Five MBP (85-99)-Specific T Cell Clones for Reactivity to a Panel of Viral/Bacterial Mimicry Peptides 
Peptide Sequence Source Hy.1B11 Ob.1A12 0b.lC3 Hy.2E11 Hy.1G11 
None 6,090 420 452 1,471 200 
2 ENPVVHFFKN I VTPR MBP(85-99) 80,102 32,631 21,171 70,350 8,859 
3 GMSL I HFLKGC I I SY Human papillomavirus 4,751 821 769 897 234 
4 SGFALHFFRLLPTAS Epstein-Barr virus 3,850 412 391 772 160 
5 FRQ LVH FVRDFAQL L Herpes simplex virus 20,164 426 402 981 157 
6 YQT I I HFARTLNRMY Parainfluenza virus type 2 4,689 393 443 531 178 
7 WRG I VHFLRYQGQEF Human papillomavirus 4,344 529 436 621 197 
8 SCTAAHF I KRF I KDG Rickettsia prowazekii 5,448 547 438 2,502 219 
9 TQRLAHFYRRWTGAK Yersinia pseudotuberculosis 4,902 414 442 924 143 
10 I VV I LFFFK I PQRLR Cytomegalovirus 3,712 444 490 963 175 
11 YVVLVQFVKHVALFS Cytomegalovirus 3,158 441 460 815 201 
12 KSLVLN FAKNEELNN Staphylococcus aureus 3,086 407 449 919 204 
13 NSNAI NFLKTWAKN Borellia burgdorferi 3,684 444 442 605 199 
14 TRPAAQFVKEAKGFT Klebsiella pneumoniae 2,912 419 454 797 221 
15 YEAMAQFFRGELRAR Herpes simplex 4,626 430 400 1,058 193 
16 SPGLVQFARATDTYF Adenovirus type 40 and 41 4,987 474 509 1,235 213 
17 AC I VL FFARRAFNKK Human cytomegalovirus 7,969 376 412 959 171 
18 I LGLLNFARNF I PNF Human spuma retrovirus 5,259 415 430 936 144 
19 VVALVNF LRH LTQKP Human cytomegalovirus 6,103 401 408 926 154 
20 PVH L L N FAR L D L I KQ Varizella-Zoste r virus 5,620 340 437 858 163 
21 FRDLLNF I RQRLCCE Human cytomegalovirus 2,619 426 510 967 144 
22 DLRVLNF I RGTKV I P Influenza A virus 3,517 486 451 741 191 
23 TVDVANFLRAYSWSD Marburg virus 3,660 434 427 1,045 175 
24 LQKALNFVRMGDRF I StaphylococCus aureus 4,868 354 344 977 213 
25 TLLL I FFYRFMRPL I Staphylococcus aureus 3,884 420 455 834 200 
26 HELLANFLRQQGGVR Pseudomonas aeruginosa 3,738 388 442 987 195 
27 SDDF I HFFKAKSYDD Dhori virus 3,373 431 459 879 651 
28 LVDEAHF I KKEAFNT Human cytomegalovirus 3,553 425 429 2,306 208 
29 TGGVYHFVKKHVHES Epstein-Barr virus 3,667 503 435 96,613 8,915 
30 EACNAHFWRDLQGEA Herpes simplex virus 3,517 494 446 1,214 224 
31 I GSQVHFYRDLSS I N Human papillomavirus 2,562 398 456 1,172 207 
32 EQVLFHFARKNGVMR Human papillomavirus 5,127 510 421 1,115 189 
33 PLGR I HFFRRGFW-FL Human cytomegalovirus 6,459 231 417 973 122 
34 I S I FLHFVR I PTHRH LCMV 8,921 342 341 944 162 
85 NGQY I HFYREPTD I K LCMV 4,408 371 401 948 209 
36 SGCYVHFFREPTDLK Lassa virus 4,687 359 388 1,094 175 
37 QESYAHF IRDSVGLP Adenovirus type 7 4,807 415 399 957 245 
38 SKYLYHYLRTLALGT HTLV-I 4,404 326 468 1,049 159 
39 NFEDWHYAKFGFTPL Human corona virus 4,809 434 367 944 184 
40 LAYSLNFLKV I QQ I L Measles virus 5,383 443 393 936 223 
41 DFEVVTFLKDVLPE F Adenovirus type 12 57,504 398 445 1,148 194 
(continued) 
recloned by limiting dilution. The subclones had the same 
specificity for MBP(85-99) and for the viral peptides as 
the parental T cell clones. Two subclones were obtained 
for Hy.1B11 (DQ1 restriction); these reacted with the 
MBP(85-99) peptide as well as with the herpesvirus, ade- 
novirus, and Pseudomonas peptides (the papil lomavirus 
peptide from the second synthesis was not tested on the 
subclones). One subclone was obtained for Hy.2E11 (DR2 
restriction); this clone reacted with MBP(85-99) as well 
as with the EBV and the influenza peptides as did the 
parental clone (the reovirus peptide from the second syn- 
thesis was not tested). In addition, previous polymerase 
chain reaction (PCR) analysis of these T cell clones using 
a panel of TCR Va and V13 family-specific primers had 
indicated that they represented clonal populations (Wuch- 
erpfennig et al., 1994b). Surface staining of clone Hy. 1 G11 
with a monoclonal  antibody specific for the Vl317.1 seg- 
ment (MAb C1, Friedman et al., 1991) showed that all cells 
expressed the Vl317.1 segment, proving that it repre- 
sented a clonal population. 
Mimicry Peptides Have Conserved Features but Are 
Quite Distinct from the MBP Peptide 
Comparison of peptide sequences that stimulate the same 
TCR revealed several interesting points. First, only one 
peptide (from human papillornavirus L2 protein) had strik- 
ing sequence similarity with the MBP(85-99) peptide, in that 
all amino acids in the MBP(89-95) segment except position 
94 (asparagine to aspartic acid) were identical (Table 2). 
For all other sequences, simple al ignment would not have 
predicted them to be efficient stimulators of MBP(85-99)- 
specific T cell clones. Second, at positions not specified 
by the search criteria, the selection for particular amino 
acids was apparent (Table 2). For example,  for the DQ1- 
restricted clone, aspartic acid was selected at position 94 
(probably a TCR contact) in all four mimicry peptides. This 
position is occupied by asparagine in the MBP peptide 
(similar size, but no negative charge). Substitution of Asn- 
94 for aspartic acid in the MBP peptide markedly increased 
its stimulatory capacity for the DQl-restr icted clone but 
reduced it for the DR2-restricted clone. Selection also oc- 
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Table 1. (continued) 
Peptide Sequence Source Hy.1B11 Ob.1A12 Ob.lC3 Hy.2E11 Hy.1G11 
42 RT LVLAFVKTCAVLA Adenovirus type 2 3,756 405 400 962 156 
43 TLMV I PFVKLDYADT Coxsackie A9 virus 3,411 427 451 744 188 
44 VEGVATFLKNPFGAF Human cytomegalovirus 3,137 426 458 786 148 
45 VGGVVSFLKNPFGGG Human herpes virus 6 3,710 338 469 774 193 
46 DSHL I CFYKRGEGLS Human cytomegalovirus 3,936 371 416 921 203 
47 VLNLLEFLKDWSGH L Epstein-Barr virus 3,913 371 410 1,055 201 
48 I NTVLCFVKSG I LLY Hepatitis A virus 4,472 374 439 1,088 197 
49 GF I AALFYKHGFNSS Hepatitis C virus 4,180 397 418 1,332 168 
50 GFLAALFYKHKFNAS Hepatitis C virus 3,581 360 468 987 202 
51 YRNLVWFVKKGNSYP !nfluenza A virus 3,628 371 399 567 183 
52 YRNLVWF I KKNTRYP influenza type A virus 3,911 368 420 45,094 5,885 
53 DLRVLSF I KGTKVVP influenza A virus 4,315 406 414 438 214 
54 SGRL I DFLKDV I ESM {nfluenza A virus 3,982 380 488 720 205 
55 GEl L I DFFKKGNLSA ~nfluenza C virus 4,908 355 425 884 161 
56 VLAL I TFFKFTALAP Japanese encephalitis virus 11,189 329 415 1,128 159 
57 I LQVLSFFKGT I I NG Newcastle disease virus 3,895 389 392 1,121 195 
58 CAAMVRFYKRGQMRE Human papillomavirus 3,428 365 410 587 161 
59 NSNAAAFLKSNSQAK Human papillomavirus 3,698 433 476 665 189 
60 TLDI LVFLKTFGGLL Parainfluenza virus type 3 4,138 399 499 708 206 
61 DLPMVTFLKDELRKK 9hinovirus type 89 4,375 365 426 453 211 
62 PKAAALFAKTYNLVP Sindbis virus 4,156 404 443 571 200 
63 DTKLAGFLKHYNSVW Rotavirus 4,185 398 376 775 169 
64 FV I VLPF I KAQNYG I ~otavirus 4,350 399 468 1,015 212 
65 YARV I DFAKFRE I AD Campylobacter jejuni 2,769 379 447 1,034 181 
66 EQFKAHYFRNVTKG E Hemophilus influenza 2,961 312 392 828 132 
67 PRAAAAFVKFNCAAL Klebsiella 5,096 355 364 631 134 
68 ERFLARFVKDYGRPA Pseudomonas aeruginosa 4,894 350 374 899 143 
69 APGAI LFAKAKHEVG Pseudomonas aeruginosa 3,965 390 305 983 163 
70 DRLLM LFAKDVVSRN Pseudomonas aeruginosa 32,872 311 373 887 169 
71 NQEAAGF I KHFEQLL Staphylococcus aureus 3,830 345 413 956 202 
72 EEKLLAFAKADKTYS Streptococcus pneumoniae 4,916 325 445 1,061 191 
The MBP(85-99) peptide (peptide 2) was used as a positive control; mimicry peptides 3-26 were from peptide set 1, mimicry peptide 27-72 from 
peptide set 2. T cell clone Hy.1 Bl l  is HLA-DQ1 restricted, clones Ob.lA12, Ob.lC3, Hy.2E11, and Hy.1Gll are HLA-DR2 restricted. Irradiated 
homozygous B cell lines were used as antigen-presenting cells: 9001 (DQ1) for clone Hy.1 B11; MGAR (DR2 [DRB1 "1501]) for clones Ob.lA12, 
Ob.lC3, Hy6.2E11, and Hy.1G11. B cells were pulsed with peptides for 2 hr at a concentration of approximately 60 i~g/ml (clones Hy.IB11, 
Ob.1A12, and Hy.IG11) and at approximately 12.5 p.g/ml for clones Ob.lC3 and Hy.2E11. After the 2 hr pulse, T cells were added (50 x 103/ 
well; final peptide concentrations: 12.5 p.g/ml and 3.1 p.g/ml, respectively). Numbers represent incorporation of [3H]thymidine that was determined 
after a 3 day culture period. Two other T cell clones (Hy.2B6 and Ob.3D1) were also tested and responded only to the M BP(85-99) peptide (data 
not shown). 
curred at the neighboring MHC contact (11e-95) for which 
isoleucine, valine, or phenylalanine were selected (all hy- 
drophobic). Third, different selection events occurred for 
the DQ1- and the DR2-restricted clones: at position 94 
(selection of aspartic acid [negative charge] for DQ1 pep- 
tides), a positive charge (lysine) was selected in two of the 
three mimicry peptides presented by DR2. Fourth, in the 
flanking segments (residues 85-87 and 97-99), no appar- 
ent selection took place as amino acids with different size 
and charge were allowed. 
The majority of the viruses are common human patho- 
gens: influenza type A frequently causes respiratory tract 
infections; human papi l lomavirus infects epithelial tissues 
and has been linked to cervical carcinomas; EBV causes 
an acute viral syndrome (infectious mononucleosis) in 
young adults. Human herpesvirus I (herpes simplex), EBV, 
and human papil lomavirus cause latent/persistent infec- 
tions; the respective reservoirs are neurons (herpes sim- 
plex), B cells (EBV), and epithelial cells (papillomavirus). 
Virus expression can be reactivated by UV exposure and 
stress (herpes simplex) and by B cell activation (EBV) 
(Schwarz  et al., 1985; Epstein and Achong,  1977; 
Spruance, 1985; Tovey et al., 1978). For the induction and 
maintenance of an autoimmune response, these persis- 
tent viral infections are of particular interest as they could 
explain the chronicity of the clinical disease and the clonal 
expansion and persistence of MBP-specific T cells. Reac- 
tivation of viral expression may also be involved in trig- 
gering clinical relapses. By this mechanism, viral mimicry 
peptides could activate resting MBP-specific T cells in pe- 
riphery and al low them to invade the CNS (Figure 4). 
Presentation of a Naturally Processed 
Viral Mimicry Peptide 
Are these mimicry epitopes actually presented to autore- 
active T cells during a viral infection? The mimicry peptide 
from the EBV DNA polymerase allowed this question to 
be addressed. In EBV-transformed B cells (which were 
used as antigen-presenting cells in the T cell assays), the 
lyric viral cycle is repressed. The DNA polymerase gene 
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Table 2. Sequence Alignment of Viral/Bacterial Mimicry Peptides 
That Stimulate MBP-Specific T Cell Clones That Are DQ1 or DR2 
Restricted 
Peptides Recognized by Clone Hy,IB11 (DO1 Restricted) 
85 90 94 99 
MBP(85-99) . ENPVVHFFKN I VTPR 
Herpes simplex, UL15 prote in  FRQLVHFVRDFAQLL 
Adenovirus type 12, ORF DFEVVTFLKDVLPEF 
Pseudomonas, phosphomannomutase DRLLMLFAKDVVSRN 
Human papillomavirus type 7, L2 protein I GGRVHFFKD I SP I A 
Peptides Recognized by Clone Hy.2E11 (DR2 Restricted) 
85 90 94 99 
MBP(85-99) ENPVVHFFKN I VTPR 
EBV, DNA po lymerase  TGGVYHFVKKHVHES 
Influenza type A, hemagglutinin YRNLVWF I KKNTRYP 
Reovirus type 3, sigma 2 protein MARAAFLFKTVGFGG 
Peptides Recognized by Clone Hy,IG11 (DR2 Restricted) 
85 90 94 99 
MBP(85-99) ENPVVHFFKN I VTPR 
EBV, DNA po lymerase  TGGVYHFVKKHVHES 
influenza type A, hemagglutinin YRNLVWF I KKNTRYP 
Herpes simplex, DNA polymerase GGRRLFFVKAHVRES 
Only the human papillomavirus peptide has obvious equence similar- 
ity with the MBP(85-99) peptide (residues identical in the 89-95 seg- 
ment are underlined). All mimicry peptides that stimulate the DQ1- 
restricted clones have aspartic acid (D) at position 94 (a putative TCR 
contact); hydrophobic residues were selected at position 95 (a putative 
MHC contact). In contrast, wo of three mimicry peptides for the DR2- 
restricted clones have a positive charge (lysine) at position 94. 
is not transcribed in this latent state; however, B cell activa- 
tion results in activation of the lytic cycle and in the expres, 
sion of the DNA polymerase gene (Datta et al., 1980). To 
examine MHC class II-restricted presentation of the EBV 
DNA polymerase, an HLA-DR2 + EBV-transformed B cell 
line (MGAR) and an MHC-mismatched control (9001, H LA- 
DR1) were pretreated for 36 hr with phorbol ester, which 
was removed by extensive washing prior to coculture of 
antigen-presenting cells with T cells. T cell clones Hy.2E11 
and Hy.IG11, which recognize the EBV DNA polymerase 
peptide presented by H LA-DR2, were activated by a H LA- 
DR2 ÷ EBV-transformed B cell line pretreated with phorbol 
ester. This effect was specific because MHC-mismatched 
B cells did not activate the clones; also, a control clone 
(Ob.1A12) that recognized M BP(85-99) but not the EBV 
peptide was not activated (Figure 3). In a separate experi- 
ment, T cell activation was blocked by a MAb specific for 
HLA-DR (MAb L243) but not by a MAb specific for HLA-DQ 
(G2a.5). These results demonstrate that the MBP-specific 
T cell clones recognize not only the viral peptide but also 
antigen-presenting cells infected with the virus. In vivo, 
this recognition event could lead to chronic antigenic stim- 
ulation of MBP-specific T cells as B cell activation results 
in the reexpression of EBV genes, including the DNA poly- 
merase gene. 
Viral Variants Differ in Their Capacity to Activate 
MBP-SpecifiC T Cell Clones 
Two peptides from different strains of influenza type A 
matched the initial search criteria; only one of them was 
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Figure 2. Efficient Stimulation of MBP(85-99)-Specific Clones by 
Mimicry Peptides 
Peptides were compared with the MBP(85-99) peptide in a titration 
experiment. The top panel shows the DR2-restricted clone (Hy.2E11) 
with MGAR (DRB1 * 1501 )as antigen-presenting cells, while the bottom 
panel shows the DQl-restricted clone (Hy.IB11) with 9001 (DQ1) as 
antigen-presenting cells. B cells were pulsed with peptides for 2 hr, 
washed, and cocultured with T cells for 3 days. Numbers represent 
cpm of incorporated [3H]thymidine as a measure of T cell proliferation. 
stimulatory for clone Hy.2E11. These two viral sequences 
were derived from the hemagglutinin subtype H13 (there 
are 13 serologically defined hemagglutinin subtypes of 
influenza type A) (Chambers et al., 1989). These hemag- 
glutinin peptides differed at four positions: the first substi- 
tution was at position 92 (isoleucine for valine), which an- 
chors the peptide to DR2; the other substitutions were at 
positions 95-97 (Table 3). Single amino acid substitutions 
demonstrated that the change at position 97 (arginine to 
serine) was responsible for the loss of reactivity (Table 3). 
This was surprising since threonine is present in the MBP 
peptide (which is structurally similar to serine) and since 
peptide position 97 was not subject to strong selection 
among the mimicry peptides (the stimulatory peptides 
have threonine, histidine, arginine, or phenylalanine at this 
position). Therefore, it is likely that this substitution affects 
the overall peptide conformation as described for MHC 
class I-bound peptides (Madden et al., 1993). These ef- 
fects on the overall peptide conformation are probably re- 
sponsible for the fact that the majority of viral peptides do 
not stimulate MBP(85-99)-specific lones. 
The observation that certain viral strains are capable of 
stimulating MBP-specific T cells while other strains are 
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Figure 3. Recognition of the Naturally Pro- 
cessed EBV DNA Polymerase Peptide by 
MBP-Specific T Cells Following Reactivation 
of EBV Transcription i B Cells 
The EBV lytic cycle is suppressed in EBV- 
transformed B cells; however, Bcell activation 
results in reactivation ofthe lytic cycle and in 
transcription of the DNA polymerase gene. A 
HLA-DR2 B cell line (MGAR) and a MHC- 
mismatched control (9001, HLA-DR1) were 
pretreated with phorbol ester (PMA, 25 ng/ml 
for 36 hr), washed, and cocultured with 
MBP(85-99)-specific T cell clones. T cell clone 
Hy.2E11 recognized both the MBP(85-99) and the EBV DNA polymerase peptide; clone Ob.1A12 that recognized only MBP(85-99) in the context 
of HLA-DR2 served as a control. Clone Hy.2E11 was activated by phorbol ester-pretreated B cells that expressed HLA-DR2 but not by MHC- 
mismatched B cells. In a separate xperiment, this effect could be blocked by a MAb specific for HLA-DR (L243) but not by a MAb specific for 
HLA-DQ (G2a.5). T cell clone Hy.IG11 that also recognized MBP(85-99) and the EBV DNA polymerase peptide were also activated by phorbol 
ester-pretreated, HLA-DR2 + B cells (data not shown). T cell proliferation assays were performed as described in Table 4. 
not may be important in defining the epidemiology of the 
disease. "Epidemic" outbreaks of MS have been noted 
(for example on the Faroe islands [Kurtzke and Hyllestad, 
1979]) that may be related to particular viral strains that 
possess strongly cross-reactive T cell epitopes. These re- 
sults also indicate that epidemiological studies will have 
to take viral subtypes and viral antigenic variation into ac- 
count. Influenza viruses are among the interesting candi- 
dates as presentation of the influenza hemagglutinin (from 
which the mimicry peptide is derived) by MHC class II 
molecules is well documented (Brown et al., 1991). 
MBP(85-99) and Its Viral Mimicry Peptides Are 
Efficiently Presented by the Disease-Associated 
DR2 Molecule 
The presentation of the viral mimicry peptides by different 
DR2 subtypes was compared to determine whether they 
are efficiently presented by the disease-associated mole- 
cule (DRB1 "1501, the most common DR2 subtype). The 
MBP peptide was presented by three of the four DR2 sub- 
types; the peptide was not presented by DRB1*1601, 
which differs from DRB1 * 1602 by a single amino acid sub- 
stitution (at position DRIP67, a possible TCR contact). The 
two viral peptides were presented much better by the 
DR15 molecules (DRB1 "1501 and 1502, which differ only 
at position DRI386) than by DRB1 * 1602. This was particu- 
larly evident for the influenza peptide, which only activated 
the T cell clone when presented by the DRB1 "1501/1502 
molecules but not by DRB1 * 1602 (Table 4). These results 
indicate that the viral mimicry peptides identified here are 
more effectively presented by the MS-associated DR2 
molecules (DRB1 * 1501/1502). 
Discussion 
This study establishes that some TCRs actually recognize 
not a single peptide but rather a limited repertoire of struc- 
turally related peptides derived from different antigens. 
This was true for three of the seven MBP(85-99)-specific 
T cell clones studied. One of these clones recognized five 
different peptides; the other clone recognized four pep- 
tides from different antigens. This recognition did not 
merely represent a minor degree of cross-reactivity, since 
these peptides efficiently activated the MBP(85-99)- 
specific clones. The other T cell clones were probably neg- 
ative because the search criteria had focused only on the 
core region of the peptide (residues 88-93) that contained 
the most important MHC and TCR contact points common 
to all clones. Several clones for which no mimicry peptides 
were identified do, however, need a longer peptide seg- 
ment than the positive clones (residues 85-97 versus resi- 
dues 87-97). It is therefore likely that mimicry peptides 
coulcl also be identified for these clones if all positions of 
the peptide were subjected to a detailed mutational analy- 
sis. As only a small fraction of the peptides that matched 
the criteria were synthesized, it is likely that many more 
peptides capable of activating MBP(85-99)-specific T cells 
could be identified. 
,Iood Brain Barrier 
Myelin Basic 
Protein Peptide 
. ~  0 ~ C N S  Antigen 
~ Presenting Cell 
Figure 4. Proposed Mechanism forActivationof MBP-SpecificTCells 
in the Peripheral Immune System by Molecular Mimicry 
Since only activated T cells can cross the blood-brain barrier, activa- 
tion of T cells specific for CNS-specific antigens occurs in the periph- 
eral immune system in the absence of the self-antigen. Viral peptides 
with sufficient structural similarity to the immunodominant MBP pep- 
tide activate these autoreactive T cells allowing them to undergo clonal 
expansion and CNS infiltration. Recognition of the MBP peptide in the 
CNS initiates the autoimmune destruction ofmyelin in the white matter 
(modified after Wucherpfennig et al., 1991). 
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Table 3. Antigenic Variation of Viral Epitopes Determines Capacity Table 4. Presentation of Viral Peptides by Subtypes of the 
for T Cell Stimulation by Molecular Mimicry Disease-Associated HLA-DRP Molecule 
MBP(85-99) 
Influenza peptide 52 (Stimulatory) 
influenza peptide 51 (Nonstimulatory) 
Point mutation position 92 (Ile to Val) 
Point mutation position 95 (Asn to Gly) 
Point mutation position 96 (Thr to Asn) 
Point mutation position 97 (Arg to Ser) 
No Peptide 
MBP(85-99) 
Influenza peptide 52 
Influenza peptide 51 
Influenza peptide 52 (92 Val) 
Influenza peptide 52 (95 Gly) 
Influenza peptide 52 (96 Asn) 

















Two influenza type A hemagglutinin peptide sequences obtained from 
different viral isolates matched the search criteria; one of these se- 
quences stimulated the DRP-restricted clone, the other peptide did 
not. Using single amino acid substitutions of the four positions different 
between these two peptides, the defective stimulation of peptide 51 
was mapped to position 97 (Arg to Ser). These results indicate that 
antigenicvariation of virusescan haveaprofound influenceon molecu- 
lar T cell mimicry. Numbers represent cpm of incorporated PH]thymi- 
dine as a measure ot T cell proliferation (mean of triplicates). 
It was, however, surprising that the majority of peptides 
did not result in T cell activation. Most likely, amino acid 
substitutions at single positions have only limited pre- 
dictive value as the simultaneous substitution of multiple 
neighboring positions may profoundly affect the peptide 
conformation. This has been elegantly demonstrated for 
MHC class i-bound peptides by comparing the crystal 
structures of HLAA2 complexed with five different pep- 
tides (Madden et al., 1993). The effect of multiple simulta- 
neous substitutions on peptide conformation makes pep- 
tides structurally more unique than appreciated by simple 
sequence comparison. The power and the novelty of the 
approach chosen in the present study is, however, demon- 
strated by the fact that the stimulatory mimicry peptides 
identified only have limited primary sequence similarity 
and would not have been predicted (with the exception of 
the papilloma virus peptide) based on simple alignments 
between MBP(85-99) and viral antigens. A better under- 
standing of the structural consequences of multiple simul- 
taneous substitutions on peptide conformation will cer- 
tainly enhance the predictive power of this approach. 
How specific is T cell recognition of MHC-peptide com- 
plexes? The molecular mimicry hypothesis postulates that 
there is significant cross-reactivity between viral T cell epi- 
topes and human self-peptides. At first sight, TCR recogni- 
tion appears to be exquisitely specific, since even minor 
substitutions in a T cell epitope can diminish or abrogate 
T cell activation (Reay et al., 1994). Several lines of evi- 
dence do, however, indicate that there is a significant de- 
gree of cross-reactivity. In shaping the TCR repertoire, 
two conflicting requirements have to be met. The first is 
comprehensive coverageof pathogen-derived epitopes by 
Peptide DRB’l501 DRB’l502 DRB”1601 DRB+l602 
No peptide 310 1,064 360 423 
MBP(85-99) 11,487 10,189 601 14,557 
EBV peptide 12,005 11,277 521 3,389 
Influenza peptide 8,266 10,079 456 412 
B cell lines homozygous for different DR2 subtypes (DRBl*1501, 
1502, 1601, and 1602) were compared for their ability to present viral 
mimicry peptides. B cell lineswere pulsed with peptides at a concentra- 
tion of 60 pglml for 2 hr, followed by washing to remove free peptide. 
Irradiated B cells (25 x 1O3) were cocultured with 50 x lo3 T cells 
for 3 days. Tcell proliferation was quantitated byPH]thymidine incorpo- 
ration. Numbers represent cpm of incorporated 13H]thymidine as a 
measure of T cell proliferation (mean of triplicates). 
production of a large panel of specificities that can deal 
with the rapidly changing antigenic composition of patho- 
gens. The second is elimination of TCRs that react with 
self-antigens that could initiate autoimmune responses. 
However, tolerance achieved by clonal deletion cannot be 
complete due to the complexity of self-antigens expressed 
in some organs, in particular the brain. The T cell receptor 
repertoire generated represents a compromise between 
these conflicting needs and allows a certain degree of 
self-reactivity in return for reasonably comprehensive cov- 
erage of foreign antigens. 
Cross-reactivity is part of the positive selection process 
in the thymus that selects T cells with low affinity for self- 
MHC molecules (plus peptide) and deletes T cells with 
higheraffinityfortheir ligand(Kappleret al., 1987; Kisielow 
et al., 1988; Sebzda et al., 1994). The relatively high fre- 
quency of alloreactive T cells also indicates that T cell 
recognition is not absolutely specific. Cytotoxic Tcells spe- 
cific for an EBV peptide bound to HLA-B8 were found to 
cross-react with HLA-B44 (Burrows et al., 1994). This allo- 
reactivity is probably the result of molecular mimicry be- 
tween the HLA-B8-bound EBV peptide and a HLA-B44- 
bound self-peptide that remains to be identified. 
Molecular mimicry may also be an important mechanism 
in experimental autoimmune diseases. Immunization of 
Lewis rats with complete Freund’s adjuvant induces a 
strong T cell response to a mycobacterial heat shock pro- 
tein 65 (hsp65) peptide. HspGBreactive T cell clones medi- 
ate arthritis by cross-reacting with ajoint proteoglycan (van 
Eden et al., 1985, 1988). While the cross-reacting joint 
peptide remains to be biochemically defined, molecular 
mimicry between hsp65 and a joint proteoglycan appears 
to be the underlying pathogenetic mechanism. Significant 
sequence similarity had also been noted between a T cell 
epitope of rabbit MBP and hepatitis B virus. Administration 
of this hepatitis B virus peptide was found to induce histo- 
logical signs of CNS inflammation and T cell reactivity to 
MBP in a polyclonal population (Fujinami and Oldstone, 
1985). 
The diverse nature of the molecular mimicry peptides 
and the ubiquitous presence of some of these pathogens 
may make it difficult to establish a direct epidemiological 
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link between these viral infections and the occurrence of 
MS. In addition, the temporal relationship between a viral 
infection and the initiation of MS is not clear in most cases, 
as the clinical diagnosis is frequently made at a time when 
magnetic resonance scans demonstrate a relatively large 
number of old lesions (Stadt et al., 1990). It may, however, 
be possible to directly demonstrate the causal relationship 
in patients with postinfectious encephalomyelitis by estab- 
lishing both virus-specific and MBP-specific T cell clones. 
The importance of molecular mimicry could also be dem- 
onstrated in MS patients with a recent viral infection (high 
IgM antibody titers to a particular virus) and magnetic reso- 
nance scans indicative of a recent onset of disease. 
The diverse nature of the viral peptides that stimulate 
MBP(85-99)-specific T cell clones makes it unlikely that 
a single virus is responsible for initiating autoimmunity in 
MS. The observation that several pathogens carry mimicry 
epitopes of MBP(85-99) could explain why it has been so 
difficult to link the immunopathogenesis of MS to a single 
viral agent. Rather, it appears that a group of common 
viral pathogens, in particular the herpes virus family (EBV, 
herpes simplex, and cytomegalovirus), influenza viruses, 
and papillomaviruses could be involved in initiating the 
autoimmune process. This notion is supported by clinical 
and epidemiological data that suggest the involvement of 
several pathogens; the observation that oligoclonal immu- 
noglobulins in the cerebrospinal fluid of MS patients are 
specific for several different viruses also points in this di- 
rection (Kurtzke, 1985; Baig et al., 1989). Childhood immu- 
nization against viral pathogens that carry mimicry T cell 
epitopes may reduce the risk of developing MS later in 
life. Genetic modifications of viral vaccines that eliminate 
proven mimicry epitopes could make viral vaccines safer 




Homozygous EBV-transformed B ceil lines used were the following: 
MGAR (DRB1*1501), 9011 (DRBl*1502), 9009 (DRBl*1601), 9016 
(DRB1*1602), and 9001 (DQ1 [DQA1 "0101, DQBI*0501]), 
Peptide Synthesis 
Mimicry peptides were synthesized on a 1 mg scale using the Multipin 
Peptide Synthesis System (Chiron Mimotopes). Peptides were synthe- 
sized on pins with a cyclic dipeptide (diketopiperazine, DKP) group 
attached to the C-terminus of the peptide that allowed cleavage in 
aqueous solution at a neutral or slightly basic pH. Peptide synthesis 
was monitored by including a standard peptide sequence as a control, 
which was subjected to HPLC and mass spectroscopy analysis. The 
immunodominant MBP(85-99) peptide was also included as a positive 
control for the T cell experiments. 
Pin peptides were lyophilized and resuspended at a concentration 
of 2 mg/ml in 40% acetonitrile, 100 mM HEPES (pH 7.4). These condi- 
tions allowed the majority of peptides to be completely solubilized. 
Preliminary experiments had indicated that adding acetonitrile to a 
final concentration of 2% or less had no detrimental effect on the 
degree of T cell stimulation observed in the proliferation assay. 
Viral and bacterial peptides that stimulated MBP(85-99)-specific 
clones were resynthesized by conventional methods (free C-terminus 
instead of the DKP group); the identity of peptides was further con- 
firmed by mass spectroscopy (using a API III Sciex Ionspray Spectrom- 
eter) and by amino acid analysis. 
Cloning of MBP(84-102)-Specific T Cells 
Previously established MBP-specific T cell clones specific for the im- 
munodominant MBP(85-99) peptide were used in this study (Wucherp- 
fen n!g e t al., 1994a, 1994b). These clones had been generated from 
blood mononuclear cells of two patients with relapsing-remitting MS 
carrying HLA-DP,2 (DR2 subtypes: DRB1*1501 for patient Ob, 
DRB1 "1602 for patient Hy). ]n both patients, the T cell response was 
focused on the immunodominant MBP(84-102) peptide. T cell lines spe- 
cific for MBP had been generated from blood mononuclear cells by 
stimulation with MBP (100 p.g/ml) in RPM11640 supplemented with 10o/0 
human serum, 2 mM L-glutamine, 10 mM HEPES, 100 U/100 pg/ml 
penicillin/streptomycin in 96-well plates at 2 x 105 cells/well (Ofa et 
aL, 1990). On day 3, IL-2 was added to 5% (Human T-Stim, Becton 
Dickinson, Bedford, MA). On day 14, an aliquot of each cell line was 
assayed for reactivity to human MBP followed by proliferation assays 
with a panel of 13 synthetic peptides encompassing the human MBP 
sequence. Following a third round of stimulation (generallytwo stimula- 
tions with MBP and one stimulation with peptide), T cell lines were 
cloned by limiting dilution using allogeneic feeder cells and phytohe- 
magglutinin (PHA) (1 p.g/ml) (Murex Diagnostics, Dartford, England) 
for stimulation. AIIogeneic MNC were irradiated with 5000 rad and 
cocultured in 96-well plates (10 s cells/well) with T cells, tL-2 was added 
on day 3, and cells were fed every 3-4 days with media containing 5% 
I L-2-containing su pernatant. On day 12-14, growth-positive wells were 
expanded by restimulation with PHA, IL-2, and allogeneic feeder cells. 
Recloning of M BP-specific clones was also done by limiting dilution 
using allogeneic feeder cells, PHA, and recombinant human IL-2 
(Boehringer Mannheim). Clones were maintained by weekly stimula- 
tion with irradiated allogeneic feeder cells, PHA, and rlL-2. Alterna- 
tively, clones were expanded by stimulation with MBP(85-99) peptide- 
pulsed B cells and rlL-2. 
T Cell Proliferation Assays 
T cell proliferation assays were done using EBV-transformed homozy- 
gous B cell lines as antigen-presenting cells. B cells were irradiated 
(5000 rad) and pulsed with peptide for 2 hr prior to addition of T cells. 
For screening of pin-peptides, 25 x 103 B cells were added per well 
of a 96-well microtiter plate in a 50 pl volume (in triplicates). Peptide 
was added to a concentration of approximately 60 I~g/ml. Following 
a 2 hr incubation at 37°C/50/O CO2, 50 x 103 T cells were added 
to a total culture volume of 200 ld/well (final peptide concentration: 
approximately 12.5 pg/ml). After 3 days, T cell proliferation was deter- 
mined with a [SH]thymidine pulse (1 p.Ci/well) and liquid scintillation 
counting. 
For MHC restriction experiments, irradiated B cells were pulsed 
with peptide for 2 hr at 37°C, followed by extensive washing. Peptide- 
pulsed B cells (25 x 103) were cocultured with 50 x 103 T cells for 
3 days; T cell proliferation was determined with a [3H]thymidine pulse 
(1 ~Ci/well) and liquid scintillation counting. 
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